TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
Organ Tech Pionee | TransMedics leads in organ transplant technology with its Organ Care System, driving a 109% year-over-year revenue increase and strong market position |
Financial Trajectory | Explore TransMedics' fiscal projections, including 2024 revenue guidance of $428-$432 million and ambitious 2028 targets of $1.2 billion revenue |
Market Dynamics | Delve into TransMedics' dominance in the DCD market and its strategic response to emerging competition from Getinge's acquisition of Paragonix |
Innovation Pipeline | Discover TransMedics' plans for next-gen OCS Lung and Heart programs, digital platform updates, and expansion into new organ transplant segments |
Metrics to compare | TMDX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipTMDXPeersSector | |
---|---|---|---|---|
P/E Ratio | 56.0x | −3.4x | −0.5x | |
PEG Ratio | 0.03 | −0.34 | 0.00 | |
Price/Book | 12.6x | 2.5x | 2.6x | |
Price / LTM Sales | 7.6x | 2.4x | 3.3x | |
Upside (Analyst Target) | 15.2% | 85.0% | 42.8% | |
Fair Value Upside | Unlock | 9.1% | 6.5% | Unlock |